Neoantigen × AI
Daily research signal
№47Brief

Personalized neoantigen vaccines advance to Phase 3 in melanoma

Today's throughline: personalized neoantigen vaccines are graduating from Phase 2 proof-of-concept to Phase 3 evidence in melanoma, while the field maps expansion into heterogeneous, recurrence-prone indications like head and neck cancer.Sutter HealthFrontiers

Underneath both sits the same bottleneck — neoantigen identification and HLA-based presentation prediction — where the translational and computational work is concentrating.Nature For investors, this is a maturing category: pivotal data in the lead indication, a growing trial pipeline in adjacent tumors, and biomarker research aimed at patient selection.

1new story2 in context
ClinicalyesterdayNew

Personalized Vaccine Targets Melanoma Recurrence? - Sutter Health

Newly released results from the international Phase 3 INTerpath-001 trial show a personalized mRNA neoantigen vaccine combined with pembrolizumab reduced the risk of melanoma recurrence or death at two years versus pembrolizumab alone, building on the Phase 2 KEYNOTE-942 evidence base. Sutter Health investigators Dr. Kevin Kim, chief of precision medicine, and Dr. Mohammed Kashani-Sabet, medical director of Sutter's CPMC Cancer Center, led Sutter's contribution to the earlier Phase 2 work. Each vaccine is built from an individual patient's tumor genetics to identify tumor-specific targets for immune attack, positioned as a post-surgical approach to prevent recurrence. Phase 3 confirmation of the vaccine-plus-checkpoint regimen in melanoma, the field's lead indication, is the category's clearest signal yet that personalized neoantigen vaccines can deliver clinical outcomes at scale — with community health systems like Sutter embedded in the evidence generation.

news · yesterday · Sutter Health

02

Relevant work from earlier we're still surfacing — not today's news.